With increasing scrutiny from regulatory bodies and a rising tide of product recalls, companies must choose between two approaches: the carrot, which symbolises incentives for quality improvement, and the stick, representing punitive measures for non-compliance. NSF experts look at the historical context, current challenges, and potential pathways for the pharma biotech sector to prioritise quality, ultimately benefiting both businesses and consumers.
The carrot and the stick: revitalising quality in the pharmaceutical industry
The pharmaceutical sector is at a critical juncture, facing immense pressure to enhance quality management systems and ensure the safety of medications
Promoted Content
You may also like
Analysis
Inspection readiness should be part of normal operations
Read moreFor routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Trending Articles
You may also like
Analysis
Inspection readiness should be part of normal operations
For routine surveillance inspections, readiness cannot depend on receiving advance notice. Inspection readiness should be embedded in everyday operations, while recognising that preparation may need to become more intensive ahead of a known regulatory milestone
Analysis
Quality culture becomes visible during an inspection
Quality culture can sound intangible, but investigators encounter evidence of it throughout an inspection. Is your quality system ready for regulatory scrutiny? Former FDA investigator Dr. Julia Marré shares practical guidance on quality culture, site preparation and effective Form FDA 483 responses